June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
IOP-lowering effects of the concomitant use of ONO-0476, a novel prostanoid EP2 receptor agonist, and existing drugs (timolol or latanoprost) in normotensive cynomolgus monkeys
Author Affiliations & Notes
  • Yoshikazu Goto
    Department of Biology & Pharmacology, Ono Pharmaceutical Co., Ltd., Mishima, Japan
  • Kazumi Moriyuki
    Department of Biology & Pharmacology, Ono Pharmaceutical Co., Ltd., Mishima, Japan
  • Shinsaku Yamane
    Department of Biology & Pharmacology, Ono Pharmaceutical Co., Ltd., Mishima, Japan
  • Yasuo Ochi
    Department of Biology & Pharmacology, Ono Pharmaceutical Co., Ltd., Mishima, Japan
  • Yasushi Hirota
    Department of Biology & Pharmacology, Ono Pharmaceutical Co., Ltd., Mishima, Japan
  • Footnotes
    Commercial Relationships Yoshikazu Goto, Ono Pharmaceutical Co., Ltd. (E); Kazumi Moriyuki, Ono Pharmaceutical Co., Ltd. (E); Shinsaku Yamane, Ono Pharmaceutical Co., Ltd. (E); Yasuo Ochi, Ono Pharmaceutical Co., Ltd. (E); Yasushi Hirota, Ono Pharmaceutical Co., Ltd. (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5710. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yoshikazu Goto, Kazumi Moriyuki, Shinsaku Yamane, Yasuo Ochi, Yasushi Hirota; IOP-lowering effects of the concomitant use of ONO-0476, a novel prostanoid EP2 receptor agonist, and existing drugs (timolol or latanoprost) in normotensive cynomolgus monkeys. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5710.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: ONO-0476 is potent and selective prostanoid EP2 receptor agonist manufactured by ONO Pharmaceutical Co., Ltd. The purpose of this study is to evaluate IOP-lowering effects of concomitant use of ONO-0476 and existing drugs (timolol or latanoprost) in normotensive cynomolgus monkeys.

Methods: Male cynomolgus monkeys received 7-day repeated topical dosing as follows: (1; ONO group) ONO-0476 (0.3 μg/mL) and vehicle in the morning (AM) and vehicle in the evening (PM), (2; ONO+TIM group) ONO-0476 and timolol (5 mg/mL) in AM and timolol in PM, (3; ONO+LAT group) ONO-0476 and latanoprost (50 μg/mL) in AM and vehicle in PM. All dosing were performed at a volume of 30 μL. IOP was evaluated by using applanation pneumatonometer just before AM dosing on day 0, and at 4, 8, 12, 24,and 48 hours after AM dosing on day 7.

Results: ONO-0476 showed potent reduction of IOP (maximal reduction of IOP in ONO group: 6.9±0.4 mmHg, n=3), and this effect is long lasting (reduction of IOP at 24 hour on day 7: 5.0±0.4 mmHg, n=3). Furthermore, concomitant use of ONO-0476 and existing drugs showed more reduction of IOP than the sole use of ONO-0476 (maximal reduction of IOP in ONO+TIM group: 7.4±0.1 mmHg, n=3, in ONO+LAT group: 8.6±0.4 mmHg, n=3).

Conclusions: ONO-0476 could provide a new and an attractive option for glaucoma therapy both as initial treatment of single use and as stepwise treatment of combination drug with other existing drugs.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×